
    
      This study administers 50.4 Gy of radiation for unresectable pancreatic cancer with
      concurrent capecitabine and an experimental drug, Bevacizumab. The drug is an antiangiogenic
      agent (kills tumor blood vessels) and has been shown in preclinical models to enhance the
      antitumor effect of radiation and chemotherapy.
    
  